Features of 24-hour monitoring of blood pressure, serum urotensin II and angiotensin II levels, vascular remodeling and extracranial blood flow in patients with hypertension
DOI:
https://doi.org/10.14739/2310-1210.2015.6.56301Keywords:
Hypertension, Carotid Intimal Medial Thickness, Blood Flow Velocity, Urotensin II, Angiotensin IIAbstract
Hypertension is the main cause of morbidity, disability and mortality in the adult population in most countries of the world.
Aim. Aiming to establish the features of 24-hour monitoring of blood pressure, serum urotensin II and angiotensin II concentrations, vascular remodeling and extracranial blood flow in patients with stage II hypertension associated with carotid atherosclerosis, cerebral blood flow indexes were studied in 102 patients using duplex scanning of extracranial arteries, 24-hour blood pressure monitoring. Serum urotensin II and angiotensin II levels were determined with immunoenzymatic method.
Results. It was found that the average 24-hour, average daytime values of systolic and diastolic blood pressure, variability indicators and blood pressure load were significantly higher in the patients of the first group of observation. Among cerebral blood flow indexes, statistically significant differences were showed by linear blood flow velocity, intima-media thickness, RI and PI. The patients with stage II hypertension associated with extracranial arterial lesions had probably higher serum urotensin II concentrations.
Conclusion. This indicates higher levels of 24-hour blood pressure monitoring indexes, severe disorders of cerebral blood flow and neurohormonal activation in case of simultaneous hypertension and atherosclerotic lesion of brachiocephalic arteries.
References
Vizir, V. A., Berezin, A. E., & Demidenko, A. V. (2007). Vzaimosvyaz' provospalitel'noj aktivacii i tyazhesti stenoticheskikh porazhenij brakhiocefal'nykh arterij ateroskleroticheskoj prirody u bol'nykh s arterial'noj gipertenziei [Relationship proinflammatory activation and severity of stenotic lesions of brachiocephalic arteries of atherosclerotic genesis in patients with hypertension]. Arterial'naya gipertenziya, 216, 14–18. [in Ukrainian].
Sirenko, Yu. M. (2009). Hipertonichna khvoroba [Hypertension]. Кyiv: Zdorovia. [in Ukrainian].
Bousette, N., Patel, L., Douglas, S.A., Ohlstein, E. H., & Giaid, A. (2004). Increased expression of urotensin-II and its cognate receptor GPR 14 in atherosclerotic lesions of the human aorta. Atherosclerosis, 176(1), 117–123. doi: http://dx.doi.org/10.1016/j.atherosclerosis.2004.03.023.
Desai, N., Sajjad, J., & Frishman, W. H. (2008). Urotensin II: a new pharmacologic target in the treatment of cardiovascular disease. Cardiol. Rev, 16(3), 142–153. doi: 10.1097/CRD.0b013e31815c8048.
Giachini, F. R., Callera, G. E., Carneiro, F. S., Tostes, R. C., & Webb, R. C. (2008). Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors? Expert opin the targets, 12(3), 327–339. doi: 10.1517/14728222.12.3.327.
Holvoet, P. (2008). Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh. K. Acad. Geneeskd belg., 70(3), 193–219.
Kompa, A.R., Thomas, W.G., See, F., Tzanidis, A., Hannan, R. D., & Krum, H. (2004). Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides, 25, 1783–1788. doi:10.1016/j.peptides.2004.03.029.
Lin, Y., Tsuchihashi, T., Matsumura, K., Fukuhara, M., Ohya, Y., Fujii, K., & Iida, M. (2003). Central cardiovascular action of urotensin II in spontaneously hypertensive rats. Hypertens. Res, 26(10), 839–845.
Maguire, J. J., & Davenport, A. P. (2002). Is urotensin-II the new endothelin? Br. J. Pharmacol, 137, 579–588.
Mori, N., Hirose, T., Nakayama, T., Ito, O., Kanazawa, M., Imai, Y., et al. (2009). Increased expression of urotensin II-related peptide and its receptor in kidney with hypertension of renal failure. Peptides, 30(2), 400–408. doi: 10.1016/j.peptides.2008.09.021.
Ong, K. L., Lam, K. S., & Cheung, B. M. (2005). Urotensin II: its function in health and its role in disease. Cardiovasc. Drugs Ther, 19, 65–75. doi: 10.1007/s10557-005-6899-x.
Schuetz, I., Witt, S. A., Glascock, B. I., Nieman, M. L., Reiser, P. J., Nix, S. L., et al. (2002). TGF-beta 1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J. Clin. Invest, 109, 787–796. doi: 10.1172/JCI14190.
Watanabe, T., Kanome, T., Miyazaki, A., & Katagiri, T. (2006). Human urotensin II as a link between hypertension and coronary artery diseases. Hypertens. Res, 29(6), 375–387. doi:10.1291/hypres.29.375.
Watanabe, T., Arita, S., Shiraishi, Y., Suguro, T., Sakai, T., Hongo, S., & Miyazaki, A. (2009). Human urotensin II promotes hypertension and atherosclerotic cardiovascular diseases. Curr. Med. Chem, 16(5), 550–563.
Watanabe, T., Suguro, T., Kanome, T., Sakamoto, Y., Kodate, S., & Hagiwara, T. (2005). Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension, 46, 738–744. doi: 10.1161/01.HYP.0000184226.99196.b5.
Watanabe, T., Takahashi, K., Kanome, T., Hongo, S., Miyazaki, A., Koba, S., et al. (2006). Human urotensin II potentials the mitogenic effect of midly oxidized low-density lipoprotein on vascular smooth muscle cells: comparison with other vasoactive agents and hydrogen peroxide. Hypertens. Res, 29, 821–831. doi:10.1291/hypres.29.821.
Yonggang, Zhanga, Yuguang, Lia, Ruihong, Weib, Zhijian, Wangc, Dingfang, Buc, Jing, Zhaoc, et al. (2008). Urotensin II is an autocrine/paracrine growth factor for aortic adventicia of rat. Regul. Pept., 151, 88–94. doi: 10.1016/j.regpep.2008.10.004.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
